Adenoviral Vector DNA- and SARS-CoV-2 mRNA-Based Covid-19 Vaccines: Possible Integration into the Human Genome - Are Adenoviral Genes Expressed in Vector-based Vaccines?
•This brief review was presented here to facilitate an independent and more balanced discussion on the potential risks due to the presence of adenovirus vector DNA (AstraZeneca, Johnson & Johnson, Sputnik V and others) or SARS-CoV-2 RNA (BioNTech/Pfizer, Moderna) in vaccines that are supposed to...
Gespeichert in:
Veröffentlicht in: | Virus research 2021-09, Vol.302, p.198466-198466, Article 198466 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •This brief review was presented here to facilitate an independent and more balanced discussion on the potential risks due to the presence of adenovirus vector DNA (AstraZeneca, Johnson & Johnson, Sputnik V and others) or SARS-CoV-2 RNA (BioNTech/Pfizer, Moderna) in vaccines that are supposed to protect against Covid-19. Of course, injections of vector-based vaccines into human deltoid muscle is a different matter than rare chance events leading to recombination events between foreign and human DNAs in experimental systems as described above. Moreover, neither type nor frequency of consequences of rare vector integration events can be realistically assessed at present. The recently published results on the benefits of protection against Covid-19 offered by the BioNTech/Pfizer vaccines are encouraging Dagan et al. 2021]. Granted, the jury is still out on whether any of the vaccines’ will protect against the more dangerous new SARS-CoV-2 variants from the UK, South Africa, Brazil and unknown variants that might arise in the future given the poorly controlled levels of viral replication around the world. Lastly, we are ignorant about vaccine protection against the development of prolonged and late-onset symptoms of Covid-19.•The information presented in this review will help future vaccinees to weigh a risk versus benefit assessment, namely the integration events of adenovirus vector or of SARS-CoV-2 RNA reverse transcript DNA at low frequency versus hopefully high vaccine efficacy and protection. Moreover, since SARS-CoV-2 infection by itself can be associated with the integration of reverse transcripts of the viral RNA [Zhang et al, 2020], this series of events might become inescapable in any SARS-CoV-2 infection. Lastly, the extent to which adenoviral gene products might become co-expressed with the SARS-CoV-2 spike glycoprotein upon vector-vaccine injection into human deltoid muscles remains un-investigated. At present we cannot gauge their possible effects on the human organism, if actually expressed. Opportunities and risks, both at the same time, remain beyond our expectations of absolute controls because life and evolution likely have been based on “chance mechanisms” from the very beginning. Clinical observations on long lasting positive RT-PCR test results that imply SARS-CoV-2 DNA integration into the human genome in the course of some Covid-19 cases, render apprehensions about vaccine-associated integration events unrealistic, when compared to the |
---|---|
ISSN: | 0168-1702 1872-7492 |
DOI: | 10.1016/j.virusres.2021.198466 |